In Vivo (Citeline) invited 20 industry leaders to share their predictions for 2026 as part of the annual “Scrip Asks””” series — selected from over 330 submissions across the biopharma sector. Max Baumann, Partner at Treehill Partners, was among the voices chosen, addressing the competitive dynamics reshaping the industry.
Under the heading “Biotech’s Existential Question”, Max challenges the assumption that biotech will continue to serve as pharma’s innovation engine. He argues that AI is poised to reshape the drug development value chain — and that as pharma seeks to bypass biotech in accessing innovative molecules directly, the sector faces mounting pressure on its core reason to exist.
The article features leaders from across the industry including executives at Bristol Myers Squibb, GSK, AbbVie, Novo Nordisk, McKinsey, and others, covering themes from dealmaking and Asia’s rise as an innovation epicenter to AI’s operational reckoning.
Read the full article: https://insights.citeline.com/in-vivo/leadership/c-suite-speaks/20-voices-what-does-2026-hold-for-biopharma-2YV26IDEUNDB3LK4K5OSZRJB7M/
📌 Treehill Partners – helping biopharma companies optimize development strategies for both regulatory approval and commercial success, unlocking transaction optionality with strategic and financial players.